AG
RLMD icon

AlTi Global’s Relmada Therapeutics RLMD Stock Holding History

AlTi Global’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Hold
31,975
– – ﹤0.01% 481
2026
Q1 		$223K Hold
31,975
– – ﹤0.01% 406
2025
Q4 		$154K Hold
31,975
– – ﹤0.01% 444
2025
Q3 		$64.3K Hold
31,975
– – ﹤0.01% 429
2025
Q2 		$19.2K Hold
31,975
– – ﹤0.01% 415
2025
Q1 		$8.63K Hold
31,975
– – ﹤0.01% 387
2024
Q4 		$16.6K Hold
31,975
– – ﹤0.01% 411
2024
Q3 		$104K Hold
31,975
– – ﹤0.01% 381
2024
Q2 		$95.9K Hold
31,975
– – ﹤0.01% 376
2024
Q1 		$149K Buy
31,975
+260
+0.8% +$1.25K ﹤0.01% 373
2023
Q4 		$131K Buy
+31,715
New +$93.9K ﹤0.01% 346

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlTi Global's RLMD Position: Q2 2026 in Review

AlTi Global held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 31,975 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #481.

AlTi Global first reported a position in RLMD in Q4 2023 and has held it in 11 quarters since. The position peaked at $223K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • AlTi Global held 31,975 shares of Relmada Therapeutics worth $221K as of Q2 2026.
  • AlTi Global left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of AlTi Global's portfolio in Q2 2026, its #481 holding.
  • AlTi Global first reported a position in Relmada Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • AlTi Global's Relmada Therapeutics position peaked at $223K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on AlTi Global's 13F filing for Q2 2026, filed 5 Aug 2026.